Filana Therapeutics, Inc.
FLNA
$0.97
-$0.03-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -35.44% | -66.75% | -81.23% | -77.63% | -66.34% |
| Gross Profit | 35.44% | 66.75% | 81.23% | 77.63% | 66.34% |
| SG&A Expenses | -32.15% | -16.36% | -36.37% | -43.72% | -82.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.35% | -48.26% | -67.61% | -62.61% | -79.03% |
| Operating Income | 33.35% | 48.26% | 67.61% | 62.61% | 79.03% |
| Income Before Tax | 80.55% | 55.86% | 54.56% | 61.32% | -818.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 80.55% | 55.86% | 54.56% | 61.32% | -818.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.55% | 55.86% | 54.56% | 61.32% | -818.51% |
| EBIT | 33.35% | 48.26% | 67.61% | 62.61% | 79.03% |
| EBITDA | 34.06% | 48.87% | 68.57% | 62.72% | 79.26% |
| EPS Basic | 80.55% | 55.89% | 54.76% | 61.59% | -787.31% |
| Normalized Basic EPS | 33.43% | 49.39% | 69.19% | 63.05% | -3,583.33% |
| EPS Diluted | 80.43% | 55.89% | 54.67% | 61.59% | -807.69% |
| Normalized Diluted EPS | 33.43% | 49.39% | 69.19% | 63.05% | -3,583.33% |
| Average Basic Shares Outstanding | 0.00% | 0.10% | 0.43% | 0.69% | 4.56% |
| Average Diluted Shares Outstanding | 0.00% | 0.10% | 0.43% | 0.69% | 4.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |